Search

Your search keyword '"Bjorge, Line"' showing total 379 results

Search Constraints

Start Over You searched for: Author "Bjorge, Line" Remove constraint Author: "Bjorge, Line"
379 results on '"Bjorge, Line"'

Search Results

1. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

2. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

3. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

4. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

5. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

6. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis

7. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer

8. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

9. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

10. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers

11. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women

12. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

13. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

14. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

15. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

16. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

17. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

18. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci

19. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

20. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

23. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration

24. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

25. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.

26. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

27. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes

28. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

29. Evidence of a genetic link between endometriosis and ovarian cancer

30. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.

31. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer

32. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.

33. Genome-wide significant risk associations for mucinous ovarian carcinoma (vol 47, pg 888, 2015)

34. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci

35. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.

36. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

37. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

38. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

40. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.

41. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

42. PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)

43. Table S1 from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

44. Online Supplementary Materials from A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

45. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

46. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Catalog

Books, media, physical & digital resources